ALK-Abelló A/S Total Assets

Latest as of December 2025: Dkr9.17 Billion DKK ≈ $1.44 Billion USD

ALK-Abelló A/S total assets. Based on the latest financial reports, ALK-Abelló A/S (ALK-B) holds total assets worth Dkr9.17 Billion DKK (≈ $1.44 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ALK-Abelló A/S (ALK-B) cash conversion ratio for how efficiently the company converts equity into cash flow.

Total Assets of ALK-Abelló A/S (2005–2025)

Total assets of ALK-Abelló A/S from 2005 to 2025. This chart illustrates how ALK-Abelló A/S's total assets have evolved over time, based on quarterly financial data. See ALK-Abelló A/S share price for real-time trading data and today's change.

ALK-Abelló A/S - Asset Composition Analysis

ALK-Abelló A/S Total Assets Breakdown (December 2025)

ALK-Abelló A/S total assets breakdown as of December 2025. ALK-Abelló A/S's total assets of Dkr9.17 Billion consist of 49.0% current assets and 51.0% non-current assets. Explore ALK-B current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Asset Category Amount (DKK) % of Total Assets
Cash & Equivalents Dkr0.00 13.5%
Accounts Receivable Dkr1.34 Billion 14.6%
Inventory Dkr1.78 Billion 19.4%
Property, Plant & Equipment Dkr0.00 0.0%
Intangible Assets Dkr1.31 Billion 14.3%
Goodwill Dkr455.00 Million 5.0%

Asset Composition Trend (2005–2025)

This chart illustrates how ALK-Abelló A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: ALK-Abelló A/S's current assets represent 49.0% of total assets in 2025, a decrease from 87.6% in 2005.
  • Cash Position: Cash and equivalents constituted 13.5% of total assets in 2025, down from 80.1% in 2005.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 2.0% in 2005.
  • Asset Diversification: The largest asset category is inventory at 19.4% of total assets.

ALK-Abelló A/S Competitors by Total Assets

Key competitors of ALK-Abelló A/S based on total assets are shown below.

Company Country Total Assets
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
USA $11.72 Billion
HLB Co. Ltd
KQ:028300
Korea ₩925.44 Billion
Tubize-Fin
BR:TUB
Belgium €1.99 Billion
Shanghai Medicilon Inc
SHG:688202
China CN¥2.88 Billion
Blue Jet Healthcare Limited
NSE:BLUEJET
India Rs16.41 Billion
Hangzhou Biotest Biotech Co Ltd
SHG:688767
China CN¥2.49 Billion
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
China CN¥725.73 Million
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
China CN¥3.67 Billion

ALK-Abelló A/S - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.38 1.69 2.33
Quick Ratio 2.04 0.81 1.30
Cash Ratio 0.00 0.00 0.00
Working Capital Dkr3.17 Billion Dkr1.34 Billion Dkr1.44 Billion

ALK-Abelló A/S - Advanced Valuation Insights

This section examines the relationship between ALK-Abelló A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 7.72
Latest Market Cap to Assets Ratio 0.85
Asset Growth Rate (YoY) 11.2%
Total Assets Dkr9.17 Billion
Market Capitalization $7.81 Billion USD

Valuation Analysis

Near Book Valuation: The market values ALK-Abelló A/S's assets close to their book value (0.85x), suggesting investors view the company's assets at approximately fair value.

Rapid Asset Growth: ALK-Abelló A/S's assets grew by 11.2% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for ALK-Abelló A/S (2005–2025)

The table below shows the annual total assets of ALK-Abelló A/S from 2005 to 2025.

Year Total Assets Change
2025-12-31 Dkr9.17 Billion
≈ $1.44 Billion
+11.23%
2024-12-31 Dkr8.25 Billion
≈ $1.29 Billion
+22.60%
2023-12-31 Dkr6.73 Billion
≈ $1.05 Billion
+6.63%
2022-12-31 Dkr6.31 Billion
≈ $986.93 Million
+8.20%
2021-12-31 Dkr5.83 Billion
≈ $912.15 Million
+4.80%
2020-12-31 Dkr5.56 Billion
≈ $870.37 Million
+1.24%
2019-12-31 Dkr5.50 Billion
≈ $859.73 Million
+12.95%
2018-12-31 Dkr4.87 Billion
≈ $761.16 Million
-1.88%
2017-12-31 Dkr4.96 Billion
≈ $775.72 Million
+3.31%
2016-12-31 Dkr4.80 Billion
≈ $750.84 Million
+12.86%
2015-12-31 Dkr4.25 Billion
≈ $665.26 Million
+24.36%
2014-12-31 Dkr3.42 Billion
≈ $534.93 Million
+4.62%
2013-12-31 Dkr3.27 Billion
≈ $511.30 Million
-0.43%
2012-12-31 Dkr3.28 Billion
≈ $513.49 Million
-2.15%
2011-12-31 Dkr3.35 Billion
≈ $524.76 Million
+18.52%
2010-12-31 Dkr2.83 Billion
≈ $442.77 Million
+6.67%
2009-12-31 Dkr2.65 Billion
≈ $415.08 Million
+4.53%
2008-12-31 Dkr2.54 Billion
≈ $397.09 Million
-10.03%
2007-12-31 Dkr2.82 Billion
≈ $441.37 Million
+1.15%
2006-12-31 Dkr2.79 Billion
≈ $436.36 Million
-59.67%
2005-12-31 Dkr6.92 Billion
≈ $1.08 Billion
--

About ALK-Abelló A/S

CO:ALK-B Denmark Biotechnology
Market Cap
$7.81 Billion
Dkr49.92 Billion DKK
Market Cap Rank
#2562 Global
#16 in Denmark
Share Price
Dkr248.00
Change (1 day)
+0.57%
52-Week Range
Dkr192.30 - Dkr270.40
All Time High
Dkr270.40
About

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more